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Mitochondrial defects within substantia nigra (SN) neurons are implicated in the pathogenesis of Parkinson’s disease. SN neurons show
increased mitochondrial defects, mitochondrial DNA deletion levels, and susceptibility to such dysfunction, although the role of mito-
chondria in neuronal degeneration remains uncertain. In this study, we addressed this important question by exploring changes within
the mitochondria of SN neurons from patients with primary mitochondrial diseases to determine whether mitochondrial dysfunction
leads directly to neuronal cell loss.We counted the pigmented neurons and quantifiedmitochondrial respiratory activity, deficiencies in
mitochondrial proteins, and the percentage of pathogenic mutations in single neurons. We found evidence of defects of both complex I
and complex IV of the respiratory chain in all patients.We found thatmarked neuronal cell loss was only observed in a few patients with
mitochondrial disease and that all these patients had mutations in polymerase gamma (POLG), which leads to the formation of multi-
plemitochondrialDNAdeletions over time, similar to aging andParkinson’s disease. Interestingly, wedetected-synuclein pathology in
twomitochondrial patients with POLGmutations. Our observations highlight the complex relationship betweenmitochondrial dysfunc-
tion and the susceptibility of SN neurons to degeneration and -synuclein pathology. Our finding that the loss of SN neurons was only
severe in patients with POLG mutations suggests that acquired mitochondrial defects may be less well tolerated by SN neurons than by
inherited ones.
Introduction
Mitochondrial dysfunction is thought to play a role in several
different neurodegenerative diseases, including Parkinson’s dis-
ease (PD) and other synucleinopathies (Abou-Sleiman et al.,
2006; Schapira, 2007; Surmeier et al., 2011; Vives-Bauza and
Przedborski, 2011). Several explanations for the increased sensi-
tivity of substantia nigra (SN) neurons to mitochondrial dys-
function have been proposed, including increased levels of iron
and calcium metabolism within this brain region. A role for this
dysfunction in the pathogenesis of PD has been strengthened
over the past few years by the discovery that several of the genes
responsible for early onset familial forms of these diseases have a
role associated with mitochondrial function, including Pink1
(PARK6 [MIM608309]), parkin (PARK2 [MIM602544]; Naren-
dra et al., 2008, 2010), and DJ-1 (PARK7 [MIM 602533]; Mitsu-
moto andNakagawa, 2001), whereas -synuclein (PARK1 [MIM
168601]) is thought to damagemitochondria directly (Devi et al.,
2008; Parihar et al., 2008). In addition, high levels of respiratory
deficiency and mitochondrial DNA (mtDNA) deletions are
found within the neurons of the SN both in patients with PD and
in normal aging (Bender et al., 2006; Kraytsberg et al., 2006).
mtDNAmutations have also been implicated as being important
for PDbased upon cybrid studies (Swerdlow et al., 1996; Gu et al.,
1998). Previous studies have shown reduced activity of mito-
chondrial complex I in SN neurons and PD-like symptoms in
response to various drugs and toxins, including MPTP and rote-
none (Burns et al., 1983; Langston et al., 1983; Schapira et al.,
1989; Betarbet et al., 2000). Despite evidence suggesting a role for
mitochondrial dysfunction in the loss of SN neurons, there re-
mains considerable uncertainty about the mechanisms involved.
Mutations within mtDNA also cause a group of diseases
termed the mitochondrial disorders, which have a minimum
prevalence of clinical manifestation in 1 in 5000 people (Schaefer
et al., 2008). Neurological defects including ataxia, seizures, de-
mentia, and stroke-like episodes are common in patients with
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mitochondrial disorders, reflecting the reliance of neurons on
mitochondrial function. Cell loss in clinically relevant brain re-
gions such as the cerebellum is correlated with changes in mito-
chondrial protein levels and cell densities (Tanji et al., 1999a,b;
Lax et al., 2012a,b). Pathogenic mutations within mtDNA can be
point mutations or large-scale deletions. Multiple mtDNA dele-
tions also occur as a result of mutations in nuclear genes, includ-
ing polymerase gamma (POLG; Hudson and Chinnery, 2006),
and Parkinsonismhas been reported in some patients with POLG
mutations (Luoma et al., 2004;Mancuso et al., 2004; Davidzon et
al., 2006; Pagnamenta et al., 2006; Tzoulis et al., 2006; Hudson et
al., 2007; Galassi et al., 2008; Invernizzi et al., 2008; Remes et al.,
2008; Betts-Henderson et al., 2009; Sato et al., 2011). To gain
further insights into the sensitivity of SN neurons to mitochon-
drial dysfunction and the effects of this dysfunction on neuronal
survival, we investigated the prevalence of mitochondrial defects
within the SN of patients with four different mtDNA disorders
caused by both point mutations and deletions. The single large-
scalemtDNAdeletions and pointmutations are present through-
out life, whereas multiple mtDNA deletions caused by POLG
mutations accumulate over time, similar to the situation in aging
and in patients with PD (Taylor and Turnbull, 2005). Therefore,
our selection of patients also enabled us to compare the effects of
inherited mtDNA mutations with those of acquired mutations
on SN neurons.
Materials andMethods
Mitochondrial disease patients
A total of 11 patients with clinically and neuropathologically confirmed
mitochondrial disease were included. All patients were severely affected
with mitochondrial disease and some had been previously included in a
study examining the pathology of cerebellar ataxia in patients with mi-
tochondrial disease (Table 1 and Lax et al., 2012a). Due to the limited
number of single large-scale deletion patients within theNewcastle Brain
Tissue Resource (NBTR), we acquired sections from a patient with a
single large-scale mtDNA deletion from Dr K. Tanji (Columbia Univer-
sity, New York, NY). Details of this patient have been described previ-
ously (Shanske et al., 1990).
Table 1 shows neurological features of these 11 patients and the pres-
ence of any extrapyramidal features that were present, as well as details of
mutations within both mitochondrial and nuclear genes. This study
encompassed patients harboring different mtDNA mutations with dif-
ferent syndromes, including two patients with mitochondrial encepha-
lomyopathy, lactic acidosis, and stroke-like episodes (MELAS) due to the
m.3243AG mutation, two patients with myoclonic epilepsy with
ragged red fibers (MERRF) due to the m.8344AG mutation, two pa-
tients with Kearns–Sayre syndrome (KSS) due to single large-scale
mtDNA deletions, and five patients with autosomal recessive mutations
in POLG with multiple mtDNA deletions. Table 2 shows a summary of
control patients used in this study, including age, sex, postmortemdelay,
cause of death, and histopathological features in the SN.
Tissue
All midbrain tissue for this study (with the exception of single deletion
case 2; Shanske et al., 1990) was obtained from theNBTR. The collection
and use of all human tissue in this study was approved by the appro-
priate local research ethics committee and conformed to the United
Kingdom Medical Research Council’s guidelines on the use of tissue in
medical research. The midbrain tissue from mitochondrial disease cases
wasmatched to an appropriate control. Patients ranged in age from 20 to
79 years (mean, 46.2) and included 6 females and 5 males. Table 1 shows
relevant clinical data for all of themitochondrial patients usedwithin this
study. Control subjects ranged in age from 48 to 70 years (mean, 56) and
included 7 males and 5 females. Details of these control subjects, includ-
ing the cause of death, can be found in Table 2. An age-matched control
was found for themajority of patients; however, finding exactmatches to
the younger mitochondrial disease cases proved more difficult.
Histology and immunohistochemistry
With the exception of the second single large-scale mtDNA deletion case
(single deletion 2), all tissue was treated identically. Due to the limited
number of single large-scale deletion cases available within theNBTR,we
were limited in the available tissue sections for this second single deletion
case. Two 20-m-thick sections of formalin-fixed paraffin-embedded
upper midbrain were taken from each case at the start and end of the
cutting series. These thick sections were stained using cresyl fast violet
(CFV) and were used for neuronal counting. Immunohistochemistry for
five mitochondrial proteins (porin, complex II [succinate dehydroge-
nase]) 70 kDa subunit, complex I (NADH:CoQ oxidoreductase) 19 kDa
subunit, complex I 20 kDa (CI20) subunit, and complex IV (cytochrome
c oxidase [COX]) subunit I (Mitosciences), -synuclein (Novacastra),
and tyrosine hydroxylase (TH; Sigma)was performed on 5mformalin-
fixed paraffin-embedded sections, as described previously (Lax et al.,
2012a; Reeve et al., 2012) on tissue from 10 cases, including single dele-
tion 2. The cells within the SN were then counted as described below.
Table 1. Summary of the patient cohort used for this study including age, sex, genotype, major neurological features, the presence of extrapyramidal involvement and
neuropathology of the SN
MELAS 1 (m.3243 AG) MELAS 2 (m.3243 AG) MERRF 1 (m.8344AG) MERRF 2 (m.8344 AG) Single deletion 1
Age (years) 20 59 42 58 40
Sex Female Female Female Male Female
Genotype m.3243AG m.3243AG m.8344AG m.8344AG m.11756-15636
Disease duration (years) 10 33 24 18 37
Major neurological features Ataxia, stroke-like episodes,
cognitive impairment,
deafness, encephalopathy
Ataxia, stroke-like episodes,
epilepsy, dementia, deaf-
ness, encephalopathy,
migraine, depression
Ataxia, deafness, myopathy,
myoclonus, depression
Ataxia, epilepsy, peripheral
neuropathy, myoclonus,
areflexia
Ataxia, dementia, encephalopathy,
depression, myopathy, CPEO, heart
block
SN pathology Normal neuronal density; pale
neuromelanin in pigmented
cells;-Syn/LB: none
Intact neuronal population
-Syn/LB: none
Moderate loss of neurons in
LMB, less pronounced in the
UMB;-Syn/LB: none
Intact neuronal population,
mild to moderate neuropil
microvacuolation;-Syn/
LB: none
Intact neuronal populations; mild to
moderate vacuolation;-Syn/LB:
none
Presence of extrapyramidal
involvement
No No No No No
Patient numbera Patient 6 Patient 1 Patient 8 N/A Patient 11
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Deficient cells were those with an absence of immunoreactivity for the
mitochondrial protein of interest. From the patients from whom frozen
material was available (controls 7, 8, 11, and 12 and all mitochondrial
disease cases with the exception of POLG1 and 2), 5 m sections were
stained for activity in complexes IV (COX) and II (succinate dehydroge-
nase [SDH]), using the previously reported COX/SDH assay (Betts et al.,
2006).
Neuronal cell counts in SN
The extent of nigral neuron loss in the 10 patients with mitochondrial
disease and the 10 age-matched controls (obtained from the NBTR)
could not be determined from dissector counts in serial sections of the
whole nigral nucleus because these were unavailable. Instead, a counting
methodwas devised based on the findings ofMa et al. (1995a, 1995b) that
dissector counts show good correlation with single two-dimensional
counts if the rostrocaudal level of the SN in the section is well defined and
the section thickness is kept constant.
Two-dimensional neuronal cell counts in the patients withmitochon-
drial disorders and the age-matched controls were performed as de-
scribed previously (Lax et al., 2012a). For each case, two 20 m sections
were cut and stained with CFV to allow identification of the SN neuronal
population and the rostrocaudal level of the SN. The SN was outlined at
low magnification (2), and then a meander scan was performed at a
higher magnification (40). This feature scans the whole region of in-
terest, allowing the absolute cell number to be determined. Cells with a
defined nucleus and nucleolus and that also contained neuromelanin
were counted. Each CFV section used in this study was then matched to
the appropriate rostrocaudal level within the control where serial sec-
tions of the midbrain were available. The neuron count was then calcu-
lated as a percentage of the neuron count at the same level within this
control.
The rostrocaudal levels of the SNwere defined from16 levels of serially
cut 20-m-thick CFV-, Loyez-, and hematoxylin/eosin-stained sections
of upper and lowermidbrain fromone normal control patient 74 years of
age. The definitions of the levels were based on relative positions and
shape of myelin fiber tracts, including cranial nerve III, medial longitu-
dinal fasciculus, medial lemniscus and its subdivisions, and decussation
of brachium conjunctivum in relation to the dorsal and ventral tiers of
the SN.
For the second single large-scale mtDNA deletion patient, only 5 m
sections were available. The cell counts could not be compared in the
same manner as above because the orientation of the section did not
allow comparison with any of the levels in the control. Therefore, the
density of the neurons within the SN was calculated based on the area of
the SN and compared with the density of neurons within a similar 5 m
section from the first single mtDNA deletion case and controls.
Determination of percentage level mutated mtDNA to
wild-type mtDNA
Sample preparation for molecular analysis. For both point mutation and
deletion level analysis, cryostat sections of uppermidbrain (20m thick)
were mounted onto PEN-membrane slides (Leica Microsystems) and
COX/SDH histochemistry was performed. Single COX-positive neurons
were dissected from the SN, collected, and lysed (LMD 6000; Leica Mi-
crosystems). Briefly, cells to be dissected are drawn around in the soft-
ware and the laser then cuts out the individual cell. To limit
contamination, we took care to cut as close to the cell boundary as pos-
sible so that we did not remove matter from the neuropil. Single cells
were cut into 500 l tubes and the tube caps inspected to verify the
presence of only one cell per tube. To limit the risk of contamination,
neurons were cut into tubes that had been UV sterilized before each
session of cutting. DNA extraction was performed at 55°C using a stan-
dard lysis buffer for a minimum of 3 h, with a proteinase K inactivation
step of 10 min at 95°C.
Pyrosequencing for pointmutations. The quantification ofmtDNAmu-
tation load in single SN neurons was performed as described previously
(Lax et al., 2012a). For this study, two pyrosequencing assays were used:
one for m.3243AG and the other for the m.8344AG mutation. The
quantification of heteroplasmy levels for mtDNA point mutations has
been validated previously (White et al., 2005). Pyrosequencing was per-
formed as per the manufacturer’s protocol (Qiagen) using a mutation-
specific pyrosequencing primer. Pyromark Q24 software (Qiagen) was
used to quantify mutated mtDNA heteroplasmy levels by comparing
directly the relevant peak heights of both wild-type and mutant mtDNA
at this site.
Real-time PCR for mtDNA deletions. A multiplex real-time PCR MT-
ND1/MT-ND4 assay was used to quantify the levels of mtDNA deletions
in individual SN neurons, as described previously (Krishnan et al., 2007;
Lax et al., 2012a). This assay detects deletions that occur within themajor
arc of mtDNA, and the majority of mtDNA deletions are thought to
occur within this region in both disease and aging (Samuels et al., 2004).
A total of 2 l of sample was used and run in triplicate in a 96-well plate.
Each run also included known deletion-level standards and a blood con-
trol, also run in triplicate.
Statistical analysis. An unpaired t test was used to compare mutation
loads between patients and controls.
Table 1. Continued
Single deletion 2 POLG 1 POLG 2 POLG 3 POLG 4 POLG 5
22 50 24 59 79 55
Female Male Female Male Male Male
m.8469-13447 p.stop1240Gln and p.Ala467Thr
with multiple mtDNA
deletions
p.Ala467Thr and p.Trp748Ser
with multiple mtDNA
deletions
p.Gly848Ser and p.Ser1104Cys
with multiple mtDNA
deletions
p.Thr251Ile and p.Ala467Thr
with multiple mtDNA
deletions
p.Trp748Ser and p.Arg1096Cys multiple
mtDNA deletions
18 22 4 37 26 40
Ataxia, seizures, intention
tremor
Ataxia, epilepsy, dementia,
peripheral neuropathy,
myoclonus, encephalopa-
thy, CPEO, myopathy,
depression
Ataxia, epilepsy, dementia,
encephalopathy, myoclo-
nus, depression
Ataxia, dementia, peripheral
neuropathy, areflexia,
depression
Ataxia, myopathy, CPEO,
dysphagia
Ataxia, cognitive decline, CPEO, myop-
athy, neuropathy, myoclonus, psy-
chosis
Unknown Severe neuronal loss;-Syn/LB:
none
Moderately severe neuronal
loss;-Syn/LB: none
Moderately severe neuronal
loss;-Syn/LB: extensive
Mild focally moderate cell loss;
-Syn/LB: extensive
Severe loss of UMB SN neurons;-Syn/
LB: none
No No No Parkinsonian symptoms No No
N/A subjectb Patient 14 Patient 12 Patient 13 N/A N/A
-Syn, Synuclein; LB, Lewy body; LMB, lower midbrain; UMB, upper midbrain; CPEO, chronic progressive external ophthalmoplegia.
aFrom Lax et al. (2012a,b).
bReported in Shanske et al. (1990).
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Results
Lewy body pathology
All cases and controls used in this study were stained for
-synuclein (for clinical and pathological data, please refer to
Tables 1 and 2). The presence of -synuclein immunoreactive
Lewy bodies, pre-Lewy bodies, and cytoplasmic granular inclu-
sions in pigmented SN neurons was used as evidence of Lewy
body pathology. None of the controls showed any immunoreac-
tivity for -synuclein within the SN. -Synuclein immunoreac-
tivity was also absent from the m.8344AG MERRF,
m.3243AG MELAS, and KSS single large-scale mtDNA dele-
tion cases despite the potential effects that mitochondrial dys-
function could have on the ubiquitin proteasome system (for
review, see Livnat-Levanon and Glickman, 2011). -Synuclein-
positive Lewy body pathology was, however, found in two of the
five POLG cases (POLG 3 and 4) used in this study, one of which
has been described previously (Betts-Henderson et al., 2009; Fig.
1). Lewy body pathology in these two cases included Lewy bodies
and neurites plus cytoplasmic granular staining of SN neurons. It
is particularly interesting that POLG patient 4 showed little cell
loss above that associated with normal aging and yet showed
severe -synuclein pathology.
Deficiency of mitochondrial proteins in SN neurons
In this study, we examined the levels of 5 mitochondrial proteins
within SN neurons in 10 patients withmitochondrial disease and
8 controls (POLG 1 and 2 of the controls were excluded from this
analysis due to an extremely long fixation time severely affecting
immunohistochemistry).We examined two subunits of complex
I of the electron transport chain [complex I 19 kDa (CI19) and
complex I 20 kDa (CI20)] because deficiencies of this protein
have been reported in patients with mtDNA disease and in both
elderly individuals and PD cases (Schapira et al., 1989; Distel-
maier et al., 2009; Lax et al., 2012a; Reeve et al., 2012). We also
examined levels of complex IV subunit I (COXI), which has been
reported previously to be correlated with activity in this complex
(Mahad et al., 2009). Complex II (CII70) was also studied be-
cause it is fully encoded by the nuclear genome and preserved in
the presence of mtDNA disease. To assess changes in mitochon-
drial density within SN neurons, we used porin, a protein on the
mitochondrial outer membrane. For complexes I and IV, the
number of SNneurons within a 5msectionwith clearly defined
nuclei were counted and the number of deficient cells calculated.
Porin and CII70 immunohistochemistry did not reveal any
difference in mitochondrial density within SN neurons between
patients with mitochondrial disease and controls (Fig. 2). There
were no neurons that showed a deficiency of complex II or porin.
Control cases (n  8) showed low levels of complex I defi-
ciency for both subunits (Fig. 3D,H). ForCI20, on average, 6.7
3.6% (mean  SD; range, 1.5–12.5%) of control SN neurons
were deficient, whereas for CI19, this value was 5.7  2.0%
(range, 1.5–8.0%; Fig. 3I). For the mitochondrial disease cases,
the level of deficiency was within the control range for the
m.3243AG MELAS cases for both CI20 (6.4% MELAS1 and
Table 2. Summary of control cases used in this study, including age, sex, post mortem delay, cause of death, and summary of the neuropathology report regarding the SN
Case Sex
Age
(years)
Post mortem
delay (h) Cause of death SN pathology
Control 1 Male 48 — — —
Control 2 Male 53 — Left ventricular failure due to ischemic heart disease Normal
Control 3 Female 56 — — —
Control 4 Female 58 — Lung cancer and Cushing’s disease Normal pigmentation with a small amount of extraneuronal neuromelanin
Control 5 Female 59 — Bowel cancer Normal
Control 6 Female 59 — — Mild neuronal loss with reduced neuromelanin
Control 7 Male 64 64 — Normal
Control 8 Male 70 72 Metastatic prostate cancer Mild age associated neuronal loss with some age related Lewy body pathology
Control 9 Female 69 16 Gastric cancer Normal pigmentation with a small amount of extraneuronal neuromelanin
Control 10 Male 65 28 Respiratory failure due to acute bronchial asthma Normal
Control 11 Male 55 41 Liver cancer Normal
Control 12 Male 50 7 Coronary artery thrombosis Normal
Figure 1. -Synuclein immunoreactivity in SN of POLG patients, a marker of Lewy body
pathology. A,B, Two of the five POLG/multiple deletion patients studied (A, POLG 3;B, POLG 4)
showed-synuclein-positive Lewy body pathology within pigmented SN neurons. Pathology
included Lewy bodies, pre Lewy bodies, cytoplasmic granular inclusions (black arrows), and
Lewy neurites (red arrows). Sections were counterstained with CFV. Images were taken at a
40magnification. Scale bar, 100m.
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4.6%MELAS2) and CI19 (4.8%MELAS1
and 5.5%MELAS2). For the m.8344AG
MERRF cases, MERRF1 showed a level of
deficiency that fell within the control
range for both CI20 (5.1%) and CI19
(3.0%), whereas MERRF2 had a higher
level of deficiency for both proteins (CI20,
22.0%; CI19, 16.3%). In tissue from pa-
tients with POLG deficiency and multiple
deletions, the level of deficiency was sig-
nificantly higher (CI20, 30.5  10.2%;
CI19, 20.8  2.9%). The highest level of
complex I deficiency, however, was found
in a patient with a single large-scale
mtDNA deletion who had a level of 44%
for CI20 and 31% for CI19; another single
deletion patient showed levels of complex
I deficiency similar to the point mutation
patients (CI20, 13.75%; CI19, 8.27%).
For COXI (Figs. 4, 5E), controls again
showed the lowest levels of deficiencies
(4.2 2.2% range, 1.1–8.0%), with cases
MELAS1 (4.08%) and MERRF2 (3.18%)
falling within this range. MELAS2 had a
slightly higher level of deficiency (8.23%),
followed by tissue from MERRF2
(22.9%). The patients with POLG defi-
ciency and multiple deletions showed
high levels of deficiency for this protein
(14.8  5.9%). Interestingly, the single
mtDNA deletion patients exhibited the
lowest levels of COXI deficiency at 0.9%
and 2.7%, respectively.
Neurons with deficiencies of complex IV activity are more
common in patients with POLG mutations
For some cases, frozen midbrain tissue was available, allowing
not only the study of mutation loads but also a comparison be-
tween the immunohistochemistry and the activity of complex IV
using COX/SDH histochemistry. This assay allows the detection
of cells with defects in the activity of complex IV (Fig. 5). The
results from this assay replicated those from the immunohisto-
chemistry. Controls and patients with point mutations
showed low levels of COX deficiency (Fig. 5E, patterned col-
umns; controls, 5.5  4.5%; MELAS1, 1.9%; MELAS2, 1.3%;
MERRF1, 7.6%; andMERRF2, 10.8%), whereas patients harbor-
ing POLG mutations and multiple mtDNA deletions showed
the highest levels (20.7 7.1%). Single deletion patient 1 exhib-
ited very low levels of COX deficiency at 0.15%, which equated to
the presence of only one COX deficient neuron shown in Figure
5.
mtDNAmutation levels are high in the SN of patients with
mitochondrial disorders
To examine the effect of the pathogenic mtDNA mutations on SN
neurons, we examined the overall heteroplasmy levels of mutations
in single neurons. Consistent with previous reports, we found that
mtDNAdeletionswerepresent incontrolneurons (mean for3cases,
25.6 4.2%; Fig. 6A) and that the percentage level of these deletions
rarely reached60% (Bender et al., 2006; Kraytsberg et al., 2006).
mtDNAdeletion levels within the POLG and single large-scale
mtDNA deletion KSS patients’ neurons, however, were much
higher than control neurons. For single large-scale mtDNA dele-
tion patient 1, the mean deletion level was 69.5 23.3%. For the
POLG patients, the mean deletion level was 57.7  2.3%. These
results show that the SN cells of patients with mtDNA disease
have a significantly (p 0.0001) higher level ofmtDNAdeletions
than controls.
The percentage levels of pathogenic point mutations were also
measured usingmutation specific pyrosequencing assays. High per-
centage levels of mutation were found in themajority of single neu-
rons (Fig. 6B), with a mean mutation load of 80% for both the
m.3243AG (MELAS) and the m.8344AG (MERRF) patients.
The heteroplasmy levels for both mtDNA deletions and point
mutations within SN neurons of these patients are comparable
to the levels recently described within the cerebellar neurons
of patients with mtDNA disease (Table 3; Lax et al., 2012a), an
area of the brain where extensive cell loss is associated with
respiratory deficiencies caused by the pathogenic mtDNA
mutation.
In COX-positive normal neurons within the SN, we found levels
ofmtDNAmutations comparable to those seenwithin the cerebellar
neurons (Table 3). It is interesting that these mutation levels were
associated with cell loss in both the cerebellum and the SN in the
patient POLG3, but in the patients with inherited defects, the levels
of mtDNAmutation within the SN comparable to levels within the
cerebellumwere not associated with cell loss.
Neuronal loss within the SN of patients with
mtDNA disorders
For each patient with mitochondrial disease and each control
used for this study, two 20 m (with the exception of single
deletion 2), CFV-stained sections of midbrain were counted us-
Figure 2. Porin immunoreactivity in SN neurons, amarker ofmitochondrial density. All pigmented SN neurons in patientswith
mitochondrial disorders showed a uniform density of mitochondria, similar to controls. A–D, Shown is KSS/single large-scale
deletion patient 1 (A), m.8344 AG point mutation patient (B), POLG/multiple deletion patients (C), and controls (D). A also
highlights themicrovacuolation thatwaswidespread throughout thebrainandmild tomoderatewithin theSNof this case. Images
were taken at a 40magnification. Scale bar, 100m.
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Figure 3. Complex I immunohistochemistry showing thevariabledegreeof proteindeficiency in SNneurons. PigmentedSNneuronswithadeficiency in complex I subunits (arrows)were found inall cases
andcontrols;however, thelevelofdeficiencyvaried.A–H, ImagesshowstainingforCI20(A–D)andCI19(E–H ),andthearrowsindicateneuronsshowingdeficienciesfortheseproteins. (Figure legendcontinues.)
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ing the stereological microscope and the
average of the two counts obtained. Al-
though there was some variation among
individuals, the mean neuron count from
10 controls expressed as a percentage of
the count from the corresponding rostro-
caudal level of SN from the normal serially
sectioned midbrain was 96  31% (Fig.
7). This variation would be expected
based on the variability between controls
from other studies (Fearnley and Lees,
1991). In addition, age-related loss of SN
neurons is known to occur in normal in-
dividuals at a rate of 4.7% per decade
(Fearnley and Lees, 1991), although the
age range of the control cases used in this
study was relatively narrow (48–70 years;
mean, 58 6.9 years; n 10). The avail-
ability of tissue from younger individu-
als was much lower than for the elderly
individuals, so finding an appropriate
match for MELAS 1 and POLG 2was par-
ticularly difficult.MELASpatients whohar-
bored the m.3243AG pathogenic point
mutation showed variable changes, with
one patient showing moderate loss of the
SN neurons and the other showing a
greater number of SN neurons than con-
trols, whereas both m.8344AG MERRF
patients showed moderate cell loss (Fig.
7). There was evidence of only mild SN
neuron loss in the patient with KSS due to
a single large-scale deletion despite the
very high levels of complex I deficiency
(COXI protein levels and COX activity
levels were normal). Althoughwe could not use the samemethod
to examine neuronal loss in the second single deletion patient
because we had only thin sections, the density of pigmented neu-
rons within the SN (10.35 cells per mm2) was comparable to that
of the other single deletion patient 1 (7.96 cells per mm2). This
suggested that, in both cases, the cell loss was minimal compared
with controls (mean cell density, 8.49 2.55 cells per mm2 for 6
control cases). The most severe SN neuron loss was seen in three
of the five POLG cases (POLG 2, POLG 3, and POLG 5), in whom
SN neuron counts were30% of controls andmore comparable
to the SN neuron loss seen in patients with PD/dementia with
Lewy bodies (DLB; Fig. 7A). This neuron loss is particularly dra-
matic when the age of the patients is taken into consideration and
could represent an acceleration of the amount of SN neuron loss
that occurs with normal aging. However, the moderate neuron
loss in POLG 1 and absence of any apparent neuron loss in POLG
4 suggest that more complex factors are involved. In addition,
the presence of -synuclein-positive Lewy body pathology in
the SN in two of the five POLG cases, one with severe loss of SN
neurons (POLG 3) and the other without any neuron loss
(POLG 4), indicates that vulnerability of SN neurons to de-
generation and susceptibility to PD/DLB -synuclein pathol-
ogy are not simple.
In a number of our patients (8/11, both m.3243AGMELAS
andm.8344AGMERRF cases, both single deletion cases, POLG
4, POLG 5, and controls 2, 4, and 8), we performed TH staining
and found that in all patients except POLG 5, between 80% and
100% of pigmented cells were TH positive. These data also con-
firm the high correlation between the two methods used for esti-
mating cell loss within the SN. In POLG 5, the percentage of
positive cells was only 60%, confirming the severe loss of dopa-
minergic cells in this case (Fig. 7B).
Extrapyramidal features in patients with
mitochondrial disease
Data from this study show that cell loss does occur within the SN
of some patients with mitochondrial disease, particularly those
harboring POLG mutations. Observing extrapyramidal involve-
ment in patients with complex neurological symptoms is diffi-
cult. POLG 3 had clear parkinsonian signs and the presence of
-synuclein-positive Lewy bodies (Betts-Henderson et al., 2009)
and Parkinsonian symptoms are well documented in patients
with POLGmutations (Luoma et al., 2004; Mancuso et al., 2004;
Davidzon et al., 2006; Pagnamenta et al., 2006; Tzoulis et al.,
2006; Hudson et al., 2007; Galassi et al., 2008; Invernizzi et al.,
2008; Remes et al., 2008; Sato et al., 2011). A lack of obvious
extrapyramidal features in the patients does not necessarilymean
that they were not present or that the loss of neurons within the
4
(Figure legend continued.) for these proteins. Deficiencies in the expression of these proteins
were found in patients with pointmutation (B, F), POLG/multiple deletions (C,G), and controls
(D, H). Images were taken at a 40 magnification. Scale bar, 100 m. I, The number of
complex I-deficient neurons was then expressed as a percentage of the total counted neurons.
Error bars show SD of controls (n 10) and PD cases (n 5).
Figure 4. COXI immunohistochemistry showing the variable degree of deficiency in SN neurons. Pigmented SN neurons with a
deficiency in COXI protein (arrows) were found in all patients with mitochondrial disease and controls, but the levels varied
between cases. A–D, The single deletion patient (A) showed negligible levels of deficiency, whereas levels of deficiency were
higher in in point mutation patients (B), POLG/multiple deletion patients (C), and controls (D). Images were taken at a 40
magnification. Scale bar, 100m.
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Figure 5. Deficiency in COX activity within SN neurons revealed by COX/SDH histochemistry. Respiratory (COX)-deficient neurons were found in the SN of all patients withmitochondrial disease
and controls usedwithin this study. However, the COX-deficient neurons (blue) were sparse in patients with KSS/single large-scale deletion (this patient had only one COX-deficient neuron; A) and
point mutations (B). POLG/multiple deletion patients (C) generally showed higher levels of COX deficiency than the patients with inherited defects. Few COX-deficient (Figure legend continues.)
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SN was not detrimental; it may be that these features were
masked by other more prominent symptoms such as ataxia
and encephalopathy.
Discussion
The primary objective of this study was to investigate how inher-
ent mitochondrial defects affect mitochondrial function and SN
neuronal survival in a group of patients withmutations known to
cause cell loss and dysfunction in other brain regions and tissues.
We have shown that the neurons of the SN are affected by mito-
chondrial dysfunction in patients with a variety of genetically
determined primarymitochondrial diseases. The level of respira-
tory chain deficiency was marked in some patients, but severe
neuron loss appeared to be more frequent in patients with muta-
tions in POLG. This is reflected in the clinical observations that
Parkinsonism is a feature repeatedly reported in patients with
POLG (Luoma et al., 2004; Mancuso et al., 2004; Davidzon et al.,
2006; Pagnamenta et al., 2006; Tzoulis et al., 2006; Hudson et
al., 2007; Galassi et al., 2008; Invernizzi et al., 2008; Remes et al.,
2008; Betts-Henderson et al., 2009; Sato et al., 2011). Deficiency
of complex I occurs in many patients, but is most severe in those
patients harboring mtDNA deletions. Changes in both the activ-
ity and level of complex IV proteins are less pronounced than for
complex I, but, again, occur inmany patients and aremost severe
in those with POLG mutations. Similar to other brain regions,
complex I deficiency in the SN, while potentially causing cell
dysfunction, does not immediately produce marked cell loss.
Similar to the cerebellum, the consequences of complex IV defi-
ciency seem to bemuch less well tolerated and there is likely to be
a progression from complex I to complex IV deficiency; it is this
more severe deficiency that has major consequences for disease
(Lax et al., 2012a).
We believe our findings shed some further light on the patho-
genesis of Parkinson’s disease and other synucleinopathies; for
example, how the mitochondrial defect and -synuclein aggre-
gation might interact with each other. We only saw -synuclein
accumulation in two patients, both with POLG mutations, and
we did not detect any -synuclein pathology in the other cases
despitemarked respiratory chain deficiency in some cases. There-
fore, although both mitochondrial defects and -synuclein are
linked to the pathogenesis of PD/DLB, the mitochondrial defect
alone is not responsible for the accumulation of -synuclein.
This is entirely compatible with our previous observations in
patients with PD/DLB in which the mitochondrial defects were
seen in neurons without -synuclein pathology (Reeve et al.,
2012).
The observation that mitochondrial defects are likely to play a
role in PD is built upon strong genetic, toxin, and animal model
studies. It is also quite striking how some patients with POLG
mutations develop clear extrapyramidal features and associated
loss of SN neurons, yet such features are not prominent in many
other patients with mitochondrial disease. In addition, as seen
even in this relatively small cohort of patients, SN involvement
was not a universal feature in all patients with POLGmutations.
Indeed, one of our patients who had both POLG mutations and
fairly extensive -synuclein pathology had little neuron loss in
the SN, confirming the variation seen in mitochondrial disease.
4
(Figure legend continued.) neurons were present in the controls (D). Images were taken at a
40magnification. Scale bar, 100m. E, Percentage of respiratory/COX-deficient neurons in
patients with mitochondrial diseases and controls compared with data from COXI immunohis-
tochemistry. Error bars showSDof controls (n10). Due to a lack of tissue availability,wewere
unable to perform COX/SDH histochemistry on all patients.
Figure6. SNneuronsofpatientswithmitochondrial disorders showhigh threshold levels for
mtDNA mutations. A, Deletion levels within single SN neurons from POLG 3 (n 45), POLG 4
(n 23), and the KSS/single large-scale deletion patient 1 (n 23) compared with controls
(n 21, 12, and 17, respectively). B, Point mutation threshold levels for m.3243 AGMELAS
and m.8344 AG MERRF patients were measured in single SN neurons and in blood cells of a
normal control using pyrosequencing (n 10).
Table 3. Comparison of themean SN neuronal mutation load to those within the
neurons of the dentate nucleus and inferior olivary nucleus and the Purkinje cells
of the cerebellum (Lax et al., 2012a)
Patient
Purkinje cell
mutation
load (%)
Inferior olivary
nucleus mutation
load (%)
Dentate nucleus
mutation load
(%)
SN mutation
load (%)
POLG 3 50.7 — 24.9 59.0
Single deletion 68.1 67.9 43.9 69.0
MELAS 1 m.3243 AG 83 — 84 87.4
MELAS 2 m.3243AG 90 93.0 77.5 80.1
MERRF 1 m.8344 AG 91.9 86.1 87.4 81.3
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Do SN neurons exposed to mitochondrial dysfunction from
early life adapt to survive?
Our data suggest that there may be differences in the severity of
SN changes seen in mitochondrial patients depending on
whether their mitochondrial defect develops with advancing age
(in the case of POLG/multiple deletion patients) or if it is present
from early development (single large-scale mtDNA deletion and
point mutation patients). Cell loss and moderate levels of defi-
ciency in complex I and complex IV seem to be associated with
the age-related accumulation of a defect, whereas very high mu-
tation levels, mitochondrial deficiencies, and relatively mild cell
loss are associated with both the single large-scale mtDNA dele-
tion patients and those patients withmtDNApointmutations. In
the latter group of patients, the defect had been present since
birth, which raises the intriguing hypothesis that SN neurons,
which are subjected to mitochondrial dysfunction from an early
stage, could have an ability to adapt to mitochondrial dysfunc-
tion to survive and maintain function. Those neurons in which a
defect develops later in life are less able to adapt and therefore are
more susceptible to the dysfunction and might be lost.
Among the possibilities to explain this
phenomenon is the possibility of an early
switch to glycolysis to maintain cellular
function. Studies with trans-mitochondrial
cybrids have suggest that high levels of mi-
tochondrial dysfunction can cause the cells
to reverse ATP synthase to maintain both
mitochondrial membrane potential and
ATP generation (Abramov et al., 2010) or
can switch to glycolysis (Pallotti et al., 2004).
A shift to glycolysis and increases in Krebs
cycle flux have also been reported in Dro-
sophila in response to mitochondrial dys-
function caused by various mutations
(Celotto et al., 2011), whereas changes in
protein expression within metabolic path-
ways have also been shown to occur in PD
(Mandel et al., 2005; Zhang et al., 2005; El-
stner et al., 2011). These studies show a de-
crease in oxidative phosphorylation genes,
tricarboxylic acidcycle, andglycolytic genes;
however, Elstner et al. (2011) showed that
the expression of most genes is stable with
agingand thatdecreasesoccur specifically in
PD. Therefore, in patients with inherited
pathogenicmtDNAmutations thatoccur in
early development, a switch to a different
energy generation could occur, allowing the
developing SN neurons to survive despite
harboring mitochondrial dysfunction,
whereas with aging and in patients with ac-
quired defects, this change does not occur.
Another possibility is a switch in the
pacemaker channels over time. The subtle
and intriguing balance between calcium
handling and mitochondrial function has
been studied in depth by Surmeier et al.
(Chan et al., 2007; Surmeier, 2007; Sur-
meier et al., 2011). SN neurons contain an
almost unique calcium channel (CaV 1.3
L type) that modulates the pacemaking
activity of these neurons (Chan et al.,
2009). Under experimental conditions,
blocking these calcium channels caused SN neurons to revert to a
juvenile form of channel that maintains this pacemaking activity
through the movement of sodium ions (Chan et al., 2007). This
switch to the juvenile channels also protects the neurons against
oxidative stress and rotenone. It is possible that SN neurons that
carry mitochondrial dysfunction from early life maintain their
juvenile channels and their pacemaking activity through sodium
rather than calcium. This would protect them against oxidative
dysfunctionwithin the SN, preventing neuron loss. This possibil-
ity remains to be investigated.
Conclusions
Mitochondrial dysfunction is common and varied within the SN
of patients with mitochondrial disorders. The accumulation of
mutations over time may be more detrimental for neuronal sur-
vival than the presence ofmitochondrial dysfunction throughout
life. These findings suggest intriguing possibilities that might un-
lock new therapeutic avenues to protect cells against mitochon-
drial dysfunction within this important brain region.
Figure 7. Pigmented neuron losswithin the SN of patientswithmitochondrial disorders.A,When expressed as a percentage neuron
countat thesamerostrocaudal levelofSNfromtheserially sectionedcontrolmidbrain, somedegreeofcell losswasseen inallpatientswith
mitochondrialdisease. Threeof fiveof thePOLG/multipledeletionpatients showedthemost severe loss,whereaspatientswithKSS/single
large-scaledeletionandpointmutations showedmilder loss. For thegroupof controls used in this study, themeancell countexpressedas
a percentage of the count at the same rostrocaudal level of the SN was 96 31%. All cases fell around the control value of 100% as
anticipated.B, Number of TH-positive neurons in a number of cases comparedwith a controlmean (n 3).
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